The estimated Net Worth of John P. Hamill is at least $511 Thousand dollars as of 13 March 2024. Mr Hamill owns over 1,010 units of Windtree Therapeutics stock worth over $47,284 and over the last 6 years he sold WINT stock worth over $0. In addition, he makes $463,553 as Sr. VP and CFO & Corp. Sec. at Windtree Therapeutics.
Mr has made over 6 trades of the Windtree Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 1,010 units of WINT stock worth $7,363 on 13 March 2024.
The largest trade he's ever made was buying 7,500 units of Windtree Therapeutics stock on 31 May 2019 worth over $8,700. On average, Mr trades about 1,072 units every 125 days since 2018. As of 13 March 2024 he still owns at least 15,503 units of Windtree Therapeutics stock.
You can see the complete history of Mr Hamill stock trades at the bottom of the page.
John P. Hamill is the Sr. VP, CFO & Corp. Sec. at Windtree Therapeutics.
As the Sr. VP and CFO & Corp. Sec. of Windtree Therapeutics, the total compensation of Mr Hamill at Windtree Therapeutics is $463,553. There are 4 executives at Windtree Therapeutics getting paid more, with Craig Fraser having the highest compensation of $1,063,640.
Mr Hamill is 57, he's been the Sr. VP and CFO & Corp. Sec. of Windtree Therapeutics since . There are 9 older and 7 younger executives at Windtree Therapeutics. The oldest executive at Windtree Therapeutics, Inc. is Mary Templeton, 73, who is the Senior Vice President, General Counsel and Corporate Secretary.
Over the last 6 years, insiders at Windtree Therapeutics have traded over $1,982,541 worth of Windtree Therapeutics stock and bought 6,849,036 units worth $20,224,921 . The most active insiders traders include James Huang, Pharmaceutical Holdings Ltd..., and Ii Investments Ltd Lph. On average, Windtree Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of $425,323. The most recent stock trade was executed by Craig Fraser on 27 September 2023, trading 2,500 units of WINT stock currently worth $2,550.
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
Windtree Therapeutics executives and other stock owners filed with the SEC include: